In the latest trading session, Smith & Wesson (SWBI) closed at $24.46, marking a -0.97% move from the previous day. This change lagged the S&P 500's 0.82% gain on the day.Prior to today's trading, shares of the firearm maker had lost 14.41% over the past month. This has lagged the Consumer Discretionary sector's loss of 0.63% and the S&P 500's gain of 3.89% in that time.Wall Street will be looking for positivity from SWBI as it approaches its next earnings report date. The company is expected to report EPS of $1.26, up 29.9% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $296.2 million, up 6.56% from the prior-year quarter.SWBI's full-year Zacks Consensus Estimates are calling for earnings of $4.40 per share and revenue of $903.4 million. These results would represent year-over-year changes of -3.08% and -18.41%, respectively.Investors might also notice recent changes to analyst estimates for SWBI. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 43.04% higher within the past month. SWBI is holding a Zacks Rank of #1 (Strong Buy) right now.Investors should also note SWBI's current valuation metrics, including its Forward P/E ratio of 5.62. This represents a discount compared to its industry's average Forward P/E of 13.05.The Leisure and Recreation Products industry is part of the Consumer Discretionary sector. This group has a Zacks Industry Rank of 22, putting it in the top 9% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Smith & Wesson Brands, Inc. (SWBI): Free Stock Analysis Report To read this article on Zacks.com click here.